ATE517121T1 - Integrin-heterodimer und eine alpha-untereinheit davon - Google Patents

Integrin-heterodimer und eine alpha-untereinheit davon

Info

Publication number
ATE517121T1
ATE517121T1 AT00939232T AT00939232T ATE517121T1 AT E517121 T1 ATE517121 T1 AT E517121T1 AT 00939232 T AT00939232 T AT 00939232T AT 00939232 T AT00939232 T AT 00939232T AT E517121 T1 ATE517121 T1 AT E517121T1
Authority
AT
Austria
Prior art keywords
subunit
integrin
alpha subunit
integrin heterodimer
marker
Prior art date
Application number
AT00939232T
Other languages
English (en)
Inventor
Donald Gullberg
Original Assignee
Cartela R & D Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20415884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE517121(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cartela R & D Ab filed Critical Cartela R & D Ab
Application granted granted Critical
Publication of ATE517121T1 publication Critical patent/ATE517121T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00939232T 1999-06-03 2000-05-31 Integrin-heterodimer und eine alpha-untereinheit davon ATE517121T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902056A SE9902056D0 (sv) 1999-06-03 1999-06-03 An integrin heterodimer and an alpha subunit thereof
PCT/SE2000/001135 WO2000075187A1 (en) 1999-06-03 2000-05-31 An integrin heterodimer and an alpha subunit thereof

Publications (1)

Publication Number Publication Date
ATE517121T1 true ATE517121T1 (de) 2011-08-15

Family

ID=20415884

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00939232T ATE517121T1 (de) 1999-06-03 2000-05-31 Integrin-heterodimer und eine alpha-untereinheit davon

Country Status (8)

Country Link
US (3) US7485429B1 (de)
EP (1) EP1181317B1 (de)
JP (2) JP2003501077A (de)
AT (1) ATE517121T1 (de)
AU (1) AU770652B2 (de)
CA (1) CA2375876A1 (de)
SE (1) SE9902056D0 (de)
WO (1) WO2000075187A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055231A1 (en) * 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
DK1345959T3 (da) 2000-11-20 2011-09-05 Univ Illinois Membranscaffoldproteiner
US7083958B2 (en) 2000-11-20 2006-08-01 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
US7622437B2 (en) 2000-11-20 2009-11-24 The Board Of Trustees Of The University Of Illinois Tissue factor compositions and methods
US7592008B2 (en) 2000-11-20 2009-09-22 The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois Membrane scaffold proteins
WO2002066989A2 (en) * 2001-02-20 2002-08-29 The Board Of Trustees Of The University Of Illinois Diagnostics, assay methods and amelioration of muscular dystrophy symptoms
DK1513877T3 (da) * 2002-06-14 2008-06-02 Cartela Ab Markör for stamceller og dens anvendelse
WO2008068481A1 (en) * 2006-12-05 2008-06-12 Cartela R & D Ab New compounds, methods and uses
WO2008075038A1 (en) * 2006-12-18 2008-06-26 Bioinvent International Ab Binding agents to the integrin alpha-11 subunit
CA2709411A1 (en) * 2006-12-18 2008-06-26 Cartela R&D Ab Binding agents to the integrin alpha-11 subunit, and uses thereof
WO2021127500A1 (en) * 2019-12-20 2021-06-24 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395929A (en) * 1987-12-15 1995-03-07 Dana Farber Cancer Institute Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor
WO1990006953A2 (en) * 1988-12-22 1990-06-28 Genentech, Inc. Method for preparing water soluble polypeptides
US5310874A (en) * 1991-05-03 1994-05-10 The Scripps Research Institute Integrin α subunit cytoplasmic domain polypeptides and antibodies
US5304603A (en) * 1991-06-18 1994-04-19 The Population Council Leydig cell stimulator
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993021226A1 (en) * 1992-04-10 1993-10-28 The General Hospital Corporation Cartilage matrix protein and methods for use
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5834248A (en) * 1995-02-10 1998-11-10 Millennium Pharmaceuticals Inc. Compositions and methods using rchd534, a gene uregulated by shear stress
EP0942931A2 (de) 1996-11-21 1999-09-22 Cor Therapeutics, Inc. Modulation der interaktionen zwischen myosin und integrinen
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
US6046316A (en) * 1997-12-09 2000-04-04 Wayne State University Nucleic acid encoding truncated integrins
AU761430B2 (en) * 1998-04-02 2003-06-05 Xintela Ab An integrin heterodimer and a subunit thereof
US20030129685A1 (en) 1998-10-28 2003-07-10 Jian Ni 12 human secreted proteins
US20030055231A1 (en) 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
EP1124850A4 (de) * 1998-10-28 2005-10-19 Human Genome Sciences Inc 12 menschliche sekretierte proteine
AU5014700A (en) 1999-05-28 2000-12-18 Millennium Pharmaceuticals, Inc. Novel integrin alphasubunit and uses thereof
EP2365004B1 (de) 2002-06-21 2016-01-06 Johns Hopkins University School of Medicine Membranassoziierte Tumorendothel-Marker
US7294290B2 (en) * 2003-08-01 2007-11-13 Ngx, Inc. Photochromic composition in a solid matrix

Also Published As

Publication number Publication date
CA2375876A1 (en) 2000-12-14
AU770652B2 (en) 2004-02-26
AU5435500A (en) 2000-12-28
EP1181317A1 (de) 2002-02-27
EP1181317B1 (de) 2011-07-20
SE9902056D0 (sv) 1999-06-03
US20090185979A1 (en) 2009-07-23
JP2003501077A (ja) 2003-01-14
WO2000075187A1 (en) 2000-12-14
JP2006246894A (ja) 2006-09-21
US7485429B1 (en) 2009-02-03
US20120114708A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
LTC1131065I2 (lt) Dialkilfumaratai, skirti autoimuninėms ligoms gydyti
BR0014652A (pt) Fabricação de conjugados de agente terapêutico-poliglutamato
MXPA02006679A (es) Composicion farmaceutica.
GEP20022804B (en) Erythropoietin Derivatives
NO170194C (no) Fremgangsmaate for fremstilling av fysiologisk aktive saarhelingsstoffer
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
ATE279938T1 (de) Reduktion des gewebe-volumens
BR0108173A (pt) Composições farmacêuticas de toxina de botulina
ES2179040T3 (es) Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.
NO20016304L (no) Erytropoetinkonjugater med polyetylenglykol, fremstilling av slike konjugater, preparater omfattende slike konjugater samt anvendelse av slike konjugater for fremstilling av medikamenter for forebygging eller behandling av sykdom
ATE517121T1 (de) Integrin-heterodimer und eine alpha-untereinheit davon
DE69422169D1 (de) Modifizierte proteine und peptide enthaltende pharmazeutische mittel
ATE329608T1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
ATE286057T1 (de) Pharmazeutische zubereitungen enthaltend clavulansäure
HUP0301349A2 (hu) IL-11-tartalmú készítmények
NO20013517D0 (no) Makrolider med anti-inflammatorisk aktivitet
ATE281155T1 (de) Medikamentöse verabreichung von proteinen aus polymergemischen
HUP9800635A2 (hu) In vivo exogén transzfekcióra és expresszióra használható gyógyászati kombináció
PA8449301A1 (es) Composiciones farmaceuticas
SE0001916D0 (sv) Novel formulation
NO995838L (no) Nye heteroetynylenforbindelser og farmasoeytiske og kosmetiske preparater inneholdende de samme
DE60036199D1 (de) Proteaseresistente flint-analoge
ATE210991T1 (de) Zusammensetzung auf der basis von pflanzenextrakten und ätherischen ölen, verwendbar in therapeutika, kosmetika und diätnahrung
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
ITRM990339A0 (it) Derivati di principi attivi ad attivita' terapeutica e/o nutrizionalee composizioni atte alla somministrazione orale contenenti tali deriva

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties